课题基金 / 基金详情

Novel Therapeutic Strategies for Pancreatic Cancer Using Next Generation Sequencing

Novel Therapeutic Strategies for Pancreatic Cancer Using Next Generation Sequencing
使用下一代测序的胰腺癌新治疗策略
批准号：
nhmrc : GNT1036603
负责人：
Dr David Chang
金额：
$35.49万
依托单位：
依托单位国家：
澳大利亚
项目类别：
Early Career Fellowships
财政年份：
2012
资助国家：
澳大利亚
项目状态：
已结题
起止时间：
2012-01-01 至 --
来源：
https://researchdata.edu.au/novel-therapeutic-strategies-generation-sequencing/1344344
关键词：
NovelTherapeuticStrategiesPancreaticCancer

项目摘要

项目成果

Dr David Chang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Dr David Chang is a surgeon scientist who specialises in the treatment of pancreatic cancer. His research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer. He aims to achieve this by utilising novel biomarkers that have the ability to forecast prognosis and response to treatments. Ultimately, this will lead to the “individualised” treatment for each patient.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing Novel Therapeutic Strategies for Pancreatic Cancer using Targets Identified by Next Generation Sequencing
  • 批准号：
    nhmrc : 1036603
  • 项目类别：
    Early Career Fellowships
  • 资助金额：
    $24.91万
  • 财政年份：
    2012
  • 负责人：
    Dr David Chang
  • 依托单位：
    Garvan Institute of Medical Research
Personalising care in operable pancreas cancer. GAP-T: a study of imaging and molecular biomarkers to guide treatment of patients receiving preoperative chemotherapy followed by surgery.
  • 批准号：
    nhmrc : 1026563
  • 项目类别：
    Project Grants
  • 资助金额：
    $27.03万
  • 财政年份：
    2012
  • 负责人：
    Dr David Chang
  • 依托单位：
    The University of Sydney
Biomarkers of phenotype, prognosis and response to therapy in pancreatic cancer.
  • 批准号：
    nhmrc : 535994
  • 项目类别：
    NHMRC Postgraduate Scholarships
  • 资助金额：
    $7.06万
  • 财政年份：
    2009
  • 负责人：
    Dr David Chang
  • 依托单位：
    Garvan Institute of Medical Research
海外基金